8-K: Cosmos Health Secures $300M Convertible Note Facility

Cosmos Health Inc. has secured a senior secured convertible promissory note facility of up to $300 million to fund its Ethereum digital asset treasury reserve strategy and general corporate purposes.

Summary

• Cosmos Health Inc. entered into a Securities Purchase Agreement with an institutional investor for the issuance of up to $300,000,000 in 9% original issue discount senior secured convertible promissory notes.
• An initial note of $8,000,000 is anticipated to be issued on August 6, 2025, with a second tranche of up to $2,000,000 upon stockholder approval and registration statement effectiveness.
• Any subsequent notes will not exceed $5,000,000 individually, and in aggregate not more than $290,000,000, subject to certain conditions and at the Company's or Buyer's election.
• Each note will mature 24 months after its respective issuance date.
• Interest accrues at 9% per annum, computed on a 360-day year, payable monthly in arrears, primarily in common stock (Interest Shares) unless an Equity Conditions Failure occurs, or the Company elects to pay in cash (Cash Interest) or a combination.
• The interest rate automatically adjusts to 16% per annum upon the occurrence and during the continuance of any Event of Default.
• The Company will use at least 72.5% of the net proceeds from each closing to acquire 'Note Purchased Crypto' (Bitcoin, Ethereum, Solana, or other mutually agreed cryptocurrencies) as a treasury asset.
• Remaining proceeds will be used for general corporate purposes and working capital, explicitly excluding satisfaction of other indebtedness (other than the Notes), redemption/repurchase of other securities, or settlement of outstanding litigation.
• The notes rank senior to all outstanding and future indebtedness of the Company and its Subsidiaries (other than Permitted Indebtedness secured by Permitted Liens) and are secured by all personal property and assets acquired using the note proceeds or proceeds of collateral.
• Collateral includes crypto assets held in blocked custodial accounts, subject to a Custodian Control Agreement, with the Collateral Agent having electronic access to custodian records.
• The Company must maintain at least $400,000 in Available Cash and cash equivalents at the end of each fiscal quarter, commencing September 30, 2025.
• A shareholder meeting must be called and held no later than 60 days after the Initial Closing Date to approve increasing authorized shares to 1,500,000,000 common and 300,000,000 preferred, and to approve the issuance of the conversion shares.
• The Company agreed to file a resale Registration Statement on Form S-3 within 45 days following the Initial Closing Date.
• The placement agent, Curvature Securities, LLC, will receive a cash fee equal to 6.0% of the aggregate gross proceeds received by the Company from the Note Offering.
• An annual commitment facility fee equal to 2.0% of the Crypto Collateral Measurement Value is payable to the Lead Buyer in cash, cryptocurrency, or common stock.
• A note holder's conversion right is limited by a 4.99% beneficial ownership limitation, which can be increased up to 9.99% upon notice to the Company.
• The Company is prohibited from effecting or entering into agreements for 'Variable Rate Transactions' (e.g., convertible securities with market-price-based conversion rates or reset features) without the prior written consent of the Required Holders.
• The Purchaser has the right to participate up to 25% in any equity or equity-linked financing of the Company until the third anniversary of the Purchase Agreement or until no Notes remain outstanding, whichever is later.
• The Company cannot effect reverse stock splits without the prior written consent of the Required Holders, unless for compliance with continued listing requirements of the Principal Market.

Sentiment

Score: 5

Explanation: The financing provides significant capital for strategic growth and a novel crypto treasury strategy, which could be transformative. However, the terms are highly dilutive and expensive, with strict covenants and high fees, indicating a challenging financing environment for the company and significant risks for shareholders.

Positives

• Secures significant capital of up to $300,000,000, providing substantial funding for strategic initiatives and working capital.
• Launches an Ethereum (ETH) digital asset treasury reserve strategy, offering shareholders direct exposure to a widely adopted digital asset.
• Proceeds are earmarked for accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and planned entry into U.S. manufacturing, indicating potential for future growth.
• The Company plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, potentially creating new revenue streams.
• The notes are senior secured, providing a level of security for the institutional investor.

Negatives

• The notes carry a high interest rate of 9% per annum, which increases significantly to 16% upon an Event of Default, indicating a high cost of capital for the Company.
• The notes are issued with an Original Issue Discount (OID), meaning the Company receives less cash ($910) than the principal amount ($1,000), further increasing the effective cost of capital.
• There is significant potential for dilution for existing shareholders due to the convertible nature of the notes and the option to pay interest in common stock.
• A substantial placement agent fee of 6.0% of gross proceeds and an annual commitment facility fee of 2.0% of the Crypto Collateral Measurement Value add to the overall cost of the financing.
• The Company is subject to strict covenants, including maintaining a minimum market capitalization of $5,000,000 and an Available Cash balance of $400,000, with failure leading to an Event of Default.
• The mandatory allocation of 72.5% of net proceeds to volatile cryptocurrency assets exposes the Company to significant market risk.
• Restrictions on future capital raises (Variable Rate Transactions) and reverse stock splits without investor consent limit the Company's financial and corporate flexibility.

Risks

• **Market Capitalization Threshold**: An Event of Default occurs if the Company's market capitalization falls below $5,000,000 for at least five trading days during any seven-trading-day period.
• **Available Cash Test**: Failure to maintain at least $400,000 in Available Cash and cash equivalents at each fiscal quarter end, commencing September 30, 2025, constitutes an Event of Default.
• **Shareholder Approval Risk**: Failure to obtain shareholder approval for increasing authorized shares to 1,500,000,000 common and 300,000,000 preferred, or for the issuance of conversion shares, constitutes an Event of Default.
• **Registration Statement Effectiveness**: Failure to file or have the resale Registration Statement declared effective by the SEC by specified deadlines (45 days for filing, 60/90 days for effectiveness) results in daily cash penalties (Registration Delay Payments) of 1.5% of the original principal amount.
• **Delisting/Suspension**: Suspension from trading or failure of common stock to be listed on an Eligible Market for three consecutive trading days, or a threatened delisting/suspension, is an Event of Default.
• **Insufficient Authorized Shares**: If the Company does not have enough authorized and unreserved shares to satisfy conversion obligations, it must pay cash for 'Authorized Failure Shares' at a premium.
• **Dilution**: The convertible nature of the notes and interest payments in shares can lead to significant dilution for existing shareholders.
• **Crypto Asset Volatility**: The strategy of holding a significant portion of proceeds in cryptocurrency (Ethereum) exposes the Company to the inherent volatility and risks of the crypto market.
• **Staking Risks**: Risks associated with staking crypto assets, including unbonding periods and potential loss of control if validators are unsatisfactory.
• **Indebtedness Default**: An Event of Default occurs if there is a default under, redemption of, or acceleration prior to maturity of at least an aggregate of $250,000 of other indebtedness of the Company or its Subsidiaries.
• **Legal/Regulatory Compliance**: Failure to comply with SEC filing requirements, Nasdaq listing rules, or other legal/regulatory obligations can trigger Events of Default.
• **Change of Control/Fundamental Transaction**: Specific redemption rights for the holder upon a Change of Control or Fundamental Transaction, potentially at a premium, could force the Company into unfavorable positions.
• **Restriction on Variable Rate Transactions**: The prohibition on certain types of future financings (Variable Rate Transactions) without investor consent could limit the Company's future capital raising flexibility.

Future Outlook

Cosmos Health plans to strategically accumulate Ethereum (ETH) to enhance long-term shareholder value and explore additional yield-generating strategies from its ETH holdings. The financing facility is intended to support accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and a planned entry into U.S. manufacturing.

Management Comments

• "This financing marks a strategic milestone for Cosmos Health, offering shareholders direct exposure to ETH, currently one of the most widely adopted digital assets in the world."
• "It also provides access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and our planned entry into U.S. manufacturing."
• "Our entry into the digital asset space is not a short-term pivot, but part of a broader commitment to innovation."
• "We are confident that the size and flexibility of this facility should position us to deliver long-term, sustainable value for our shareholders."

Industry Context

This financing positions Cosmos Health as an early adopter among healthcare groups to integrate a significant digital asset treasury strategy, specifically with Ethereum. This move aligns with broader trends of digital transformation and the exploration of blockchain use cases in supply chain traceability, wellness incentive programs, and global consumer engagement, potentially differentiating the company from traditional healthcare competitors.

Comparison to Industry Standards

• While a crypto treasury strategy is innovative for a healthcare group, the specific terms of this financing facility, including the high interest rate (9% increasing to 16% on default), significant original issue discount (9% discount), and substantial placement agent fees (6%), appear more onerous than typical corporate debt or equity raises for established companies.
• The strict covenants, such as the market capitalization and available cash thresholds, suggest a higher risk profile perceived by the institutional investor, potentially indicating that traditional financing avenues were less favorable or unavailable.
• Direct comparisons to other healthcare companies with similar crypto treasury strategies are not readily available, as this remains a nascent trend in the sector.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to convertible notes and interest payable in shares. Exposure to cryptocurrency market volatility. Potential long-term value enhancement if crypto strategy and growth initiatives succeed.
• **Investors (Noteholders)**: Senior secured position provides protection. High interest rate and premiums offer attractive returns. Control provisions and covenants provide significant oversight.
• **Company Operations**: Access to capital for strategic growth, R&D, and U.S. manufacturing expansion. Mandatory crypto allocation limits immediate operational cash flexibility.

Next Steps

• Issuance and sale of the Initial Note ($8,000,000) on August 6, 2025.
• Acquisition of Note Purchased Crypto with 72.5% of net proceeds from each closing.
• Company to call and hold an annual meeting of stockholders within 60 days of the Initial Closing Date to approve increasing authorized shares and the issuance of conversion shares.
• Company to file a resale Registration Statement on Form S-3 within 45 days of the Initial Closing Date.
• Company to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings.
• Company plans to enter U.S. manufacturing.

Key Dates

Recommendation

The financing provides Cosmos Health with substantial capital to pursue strategic growth initiatives and a novel Ethereum treasury strategy, which could be transformative for the company. However, the terms of the convertible notes are highly dilutive and expensive, including a significant original issue discount, high interest rate, and substantial fees. The strict covenants and mandatory allocation to volatile crypto assets introduce considerable risk. Given the mixed signals of strategic potential versus high cost and risk, a 'hold' recommendation is appropriate, advising investors to monitor execution of the crypto strategy and financial performance closely.

Keywords

Convertible Notes, Secured Financing, Ethereum Treasury, Digital Assets, COSM, Cosmos Health, SEC Filing, Private Placement, Dilution, Corporate Governance, Risk Management, Healthcare Group, Nasdaq, Cryptocurrency, Staking